Harada Takeshi, Abe Masahiro
Nihon Rinsho. 2014 Jun;72(6):1143-8.
Over the past decade, monoclonal antibodies (mAbs) have been demonstrated to be powerful therapeutic options for hematological diseases. MAbs exert selective therapeutic effects through binding specific molecules, which can minimize the frequency and magnitude of their adverse effects. The major mechanisms of the cytotoxic activity by mAbs against hematological malignancies are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). To enhance the ADCC activity, the defucosylated version of mAbs have been developed to enhance their binding ability to Fcgamma receptor IIIa. Antibody-drug conjugates and radiolabeled mAbs are also designed to selectively kill tumor cells. Owing to the recent innovation of mAb generation and modification techniques, we can expect more benefical mAbs with diverse functions as important therapeutic strategies.
在过去十年中，单克隆抗体（mAbs）已被证明是血液系统疾病强有力的治疗选择。单克隆抗体通过结合特定分子发挥选择性治疗作用，这可以将其不良反应的频率和严重程度降至最低。单克隆抗体针对血液系统恶性肿瘤的细胞毒性活性的主要机制是补体依赖性细胞毒性和抗体依赖性细胞毒性（ADCC）。为了增强ADCC活性，已开发出去岩藻糖基化的单克隆抗体版本以增强其与Fcγ受体IIIa的结合能力。抗体-药物偶联物和放射性标记的单克隆抗体也被设计用于选择性杀死肿瘤细胞。由于单克隆抗体制备和修饰技术的最新创新，我们可以期待更多具有多种功能的有益单克隆抗体作为重要的治疗策略。
